^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BMS-986179

    i
    Other names: BMS-986179, BMS 986179, BMS986179
    Associations

    News

    Trials
    Company:
    BMS
    Drug class:
    CD73 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3years
    An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov)
    P1/2, N=268, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Nov 2020 --> Feb 2023
    Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD73 (5'-Nucleotidase Ecto)
    |
    CD73 expression
    |
    Opdivo (nivolumab) • BMS-986179